Persistent Use of Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Significant Clinical & Economic Benefits Compared to Conventional Insulin Delivery in Patients with Type 2 Diabetes

Valeritas Holdings, Inc. announced today the publication this week of a manuscript titled “Clinical and Economic Considerations Based on Persistency with a Novel Insulin Delivery Device versus Conventional Insulin Delivery in Patients with Type 2 Diabete https://globenewswire.com/news-release/2018/10/10/1619072/0/en/Persistent-Use-of-Valeritas-V-Go-Wearable-Insulin-Delivery-Device-Demonstrates-Significant-Clinical-Economic-Benefits-Compared-to-Conventional-Insulin-Delivery-in-Patients-with-Typ.html